Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma
暂无分享,去创建一个
Yong Teng | Chloe Shay | Yong Teng | Xu-li Wang | C. Shay | Yuanping Xiong | Liwei Lang | Liwei Lang | Xiangdong Zhao | Xuli Wang | Yuanping Xiong | Xiangdong Zhao
[1] J. Yang,et al. Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer , 2019, Experimental & Molecular Medicine.
[2] Martin Gs. The hunting of the Src. , 2001 .
[3] Yong Teng,et al. Nck-associated protein 1 associates with HSP90 to drive metastasis in human non-small-cell lung cancer , 2019, Journal of Experimental & Clinical Cancer Research.
[4] W. Messersmith,et al. Current status of SRC inhibitors in solid tumor malignancies. , 2011, The oncologist.
[5] Faye M. Johnson,et al. Regulation of Src Family Kinases in Human Cancers , 2011, Journal of signal transduction.
[6] Yong Teng,et al. FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19/FGFR4 signaling in head and neck squamous cell carcinoma , 2018, Oncogene.
[7] J. Baselga,et al. The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy , 2006, Clinical Cancer Research.
[8] T. Yeatman,et al. Role of Src expression and activation in human cancer , 2000, Oncogene.
[9] Rebecca L. Siegel Mph,et al. Cancer statistics, 2016 , 2016 .
[10] A. Egloff,et al. Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. , 2008, Seminars in oncology.
[11] M. Hung,et al. HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway* , 2000, The Journal of Biological Chemistry.
[12] M. Sheetz,et al. EGFR family and Src family kinase interactions: mechanics matters? , 2018, Current opinion in cell biology.
[13] N. Sharma,et al. Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors , 2017, Clinical Cancer Research.
[14] Mohammad A. Ghattas,et al. Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters. , 2010, Cancer research.
[15] Kuen-Feng Chen,et al. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells. , 2012, Neoplasia.
[16] B. Telfer,et al. Akt inhibition improves long‐term tumour control following radiotherapy by altering the microenvironment , 2017, EMBO molecular medicine.
[17] T. Chou. Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.
[18] Yong Teng,et al. Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib , 2018, Journal of Hematology & Oncology.
[19] C. Tepper,et al. The Src Inhibitor AZD0530 Blocks Invasion and May Act as a Radiosensitizer in Lung Cancer Cells , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[20] L. Zhang,et al. Increased expression of Cathepsin B in oral squamous cell carcinoma. , 2010, International journal of oral and maxillofacial surgery.
[21] A. Jemal,et al. Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.
[22] J. Grandis,et al. New Therapies in Head and Neck Cancer. , 2018, Trends in cancer.
[23] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[24] Huaidong Jiang,et al. Carbon-dot-supported atomically dispersed gold as a mitochondrial oxidative stress amplifier for cancer treatment , 2019, Nature Nanotechnology.
[25] W. A. Yeudall,et al. MTS1/CDK4I is altered in cell lines derived from primary and metastatic oral squamous cell carcinoma. , 1994, Carcinogenesis.
[26] R. Finn,et al. Targeting Src in breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] A. Baras,et al. Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer , 2017, Clinical Cancer Research.
[28] J. Ensley,et al. Tyrosine phosphorylation as a marker for aberrantly regulated growth‐promoting pathways in cell lines derived from head and neck malignancies , 1995, International journal of cancer.
[29] Yong Teng,et al. Autophagy blockade sensitizes human head and neck squamous cell carcinoma towards CYT997 through enhancing excessively high reactive oxygen species-induced apoptosis , 2018, Journal of Molecular Medicine.
[30] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[31] J. Siegfried,et al. c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met , 2012, Clinical Cancer Research.
[32] J. Barrett,et al. A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers , 2017, Clinical Cancer Research.
[33] V. Papadimitrakopoulou,et al. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma , 2011, Cancer.
[34] Doris Berger. The hunting of the src , 2014, Im Focus Onkologie.
[35] Simion I. Chiosea,et al. Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. , 2017, JCI insight.